Skip to main content

Table 1 Characteristics of lung cancer patients by low-dose aspirin use

From: Low-dose aspirin and survival from lung cancer: a population-based cohort study

Characteristics Total study population Low-dose aspirin use in year prior to diagnosisa Low-dose aspirin use after diagnosisb
   User n (%) Non-user (%) Ever n (%) Never (%)
  (n = 14,735) (n = 13,433) (n = 3,635)
Year of diagnosis: 1998–2000 2,797 (19) 459 (12) 1,850 (19) 175 (15) 463 (19)
 2001–2003 3,708 (25) 831 (22) 2,524 (26) 280 (24) 603 (24)
 2004–2006 4,025 (27) 1,175 (30) 2,603 (27) 322 (28) 647 (26)
 2007–2009 4,205 (29) 1,404 (36) 2,587 (27) 384 (33) 761 (31)
Age at diagnosis: < 50 492 (3) 11 (0) 410 (4) 10 (1) 163 (7)
 50–59 1,780 (12) 171 (4) 1,425 (15) 97 (8) 475 (19)
 60–69 3,912 (27) 916 (24) 2,660 (28) 362 (31) 804 (33)
 70–79 5,347 (36) 1,681 (44) 3,231 (34) 478 (31) 775 (31)
 80–89 2,898 (20) 974 (25) 1,677 (18) 199 (17) 242 (10)
 ≥90 306 (2) 116 (3) 161 (2) 15 (1) 15 (1)
Gender: Males 8,701 (59) 1,581 (63) 6,360 (58) 748 (64) 1,357 (55)
Treatment within 6 months of cancer diagnosis
 Surgeryc 1,324 (12) 329 (11) 895 (12) 305 (34) 567 (30)
 Chemotherapy 3,287 (22) 709 (18) 2,324 (24) 309 (27) 950 (38)
 Radiotherapy 4,668 (32) 1,129 (29) 3,100 (32) 389 (34) 989 (40)
Histology: Non-small cell 8,224 (56) 2,066 (53) 5,478 (57) 822 (71) 1,793 (73)
 Small cell 1,828 (12) 458 (12) 1,218 (13) 121 (10) 303 (12)
 Missing 4,683 (32) 1,345 (35) 2,868 (30) 218 (19) 378 (15)
Smoking status prior to cancer diagnosis
 Non-smoker 1,907 (13) 543 (14) 1,188 (12) 148 (13) 339 (14)
 Ex-smoker 5,214 (35) 1,754 (45) 3,111 (33) 541 (47) 852 (34)
 Current smoker 5,961 (41) 1,329 (34) 4,138 (43) 393 (34) 1,042 (42)
 Missing 1,653 (11) 243 (6) 1,127 (12) 79 (7) 241 (10)
Alcohol consumption prior to diagnosis
 Never 2,311 (16) 727 (19) 1,385 (15) 190 (16) 342 (14)
 Ever 9,707 (66) 2,678 (69) 6,337 (66) 841 (72) 1,712 (69)
 Missing 2,717 (18) 464 (12) 1,842 (19) 130 (11) 420 (17)
BMI (kg/m2) prior to diagnosis: mean (sd)
 Underweight (<18.5) 735 (5) 175 (5) 487 (5) 38 (3) 100 (4)
 Normal (18.5 to 25) 5,325 (36) 1,379 (36) 3,543 (37) 401 (35) 943 (38)
 Overweight (25–30) 3,916 (27) 1,199 (31) 2,444 (26) 388 (33) 695 (28)
 Obese (>30) 1,702 (12) 602 (16) 1,002 (11) 196 (17) 287 (12)
 Missing 3,057 (21) 514 (13) 2,088 (22) 138 (12) 449 (18)
Deprivation fifth: 1st (least deprived) 2,583 (18) 650 (17) 1,696 (18) 206 (18) 481 (19)
 2nd 2,822 (19) 754 (20) 1,833 (19) 236 (20) 451 (18)
 3rd 2,975 (20) 778 (20) 1,954 (20) 232 (20) 492 (20)
 4th 3,235 (22) 815 (21) 2,102 (22) 250 (22) 556 (23)
 5th (most deprived) 3,062 (21) 859 (22) 1,947 (20) 233 (20) 489 (20)
 Missing 58 (0) 13 (0) 32 (0) 4 (0) 5 (0)
Comorbidity prior to cancer diagnosis
 Cerebrovascular disease 1,.325 (9) 746 (19) 498 (5) 147 (13) 95 (4)
 Chronic pulmonary disease 3,619 (25) 1,054 (27) 2,341 (25) 307 (26) 621 (25)
 Congestive heart disease 954 (7) 413 (11) 483 (5) 83 (7) 76 (3)
 Diabetes 1,552 (11) 758 (20) 698 (7) 194 (17) 141 (6)
 Myocardial infarction 1,262 (9) 866 (22) 316 (3) 223 (19) 67 (3)
 Peptic ulcer disease 1,087 (7) 264 (7) 745 (8) 65 (6) 182 (7)
 Peripheral vascular disease 1,422 (10) 780 (20) 576 (6) 200 (17) 127 (5)
 Renal disease 864 (6) 441 (11) 397 (4) 97 (8) 99 (4)
Other medication use after diagnosis
 Statin used 4,801 (33) 2,103 (54) 1,193 (13) 705 (61) 410 (17)
 Beta-blocker used 3,823 (26) 1,143 (30) 1,005 (11) 416 (36) 272 (11)
  1. aAnalysis includes lung cancer patients who have more than 1 year of records prior to diagnosis
  2. bPost-diagnostic aspirin use (regardless of pre-diagnostic aspirin use), among lung cancer patients who lived more than 1 year after diagnosis
  3. cExcluding cancer patients from Thames Registry as surgery information not available
  4. dStatin and beta-blocker use ever after diagnosis for low-dose aspirin use after diagnosis columns, statins and beta-blocker use in year prior to diagnosis for low-dose aspirin use in year prior to diagnosis columns, statins and beta-blocker use either before or after diagnosis in total study population column